Literature DB >> 35066758

Roles of circ_0000135/miR-140-3p/PDZK1 network in cervical cancer.

N Wang1, Y Zheng1, X Zhang1, S W Xu1, X H Li1, Y L Meng1, J Q Liu2.   

Abstract

PURPOSE: To explore the effect of circ_0000135/miR-140-3p/PDZ domain containing 1 (PDZK1) on the occurrence and development of cervical cancer.
METHODS: Clinical data were collected to verify circ_0000135/miR-140-3p/PDZK1 expression in cervical cancer. mRNA expressions of circ_0000135 and miR-140-3p were detected by real-time quantitative PCR. Correlation between circ_0000135 and miR-140-3p/miR-140-3p and PDZK1 was analyzed in vitro. Protein expression detection in cells was conducted by Western blot; while cell proliferation, invasion and cycle distribution by CCK8 assay, Transwell chamber assay and flow cytometry, respectively. Rescue and animal experiment were performed to verify the effect of circ_0000135/miR-140-3p/PDZK1 on cervical cancer.
RESULTS: circ_0000135 and PDZK1 expressions were increased, while those of miR-140-3p were decreased in cervical cancer tissues and cells (both P < 0.05). sh-circ_0000135 group had decreased cell viability, arrested cells in G0/G1 phase, decreased CyclinD1 expression, inhibited cell migration and invasion; sh-circ_0000135 group showed reduced tumor volume, weight, and lower Ki67 expression (all P < 0.05). circ_0000135 had conserved target of miR-140-3p. There was a direct interaction between circ_0000135 and miR-140-3p. miR-140-3p might have direct interaction with PDZK1. sh-circ_0000135 and/or miR-140-3p treatment showed obviously decreased PDZK1 expression, decreased cell activity, arrested cells in G0/G1 phase, downregulated cell migration and invasion; sh-circ_0000135 and/or miR-140-3p mimic treatment showed obviously decreased tumor volume, tumor weight, and Ki67 expression (all P < 0.05).
CONCLUSION: circ_0000135 may play an anti-tumor role on the progression of cervical cancer by sponging miR-140-3p to suppress the expression of PDZK1, providing a promising therapeutic target.
© 2021. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  Cervical cancer; Invasion; PDZK1; Proliferation; circ_0000135; miR-140-3p

Mesh:

Substances:

Year:  2022        PMID: 35066758     DOI: 10.1007/s12094-021-02751-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  5 in total

1.  Microarray analysis of gene expression in the ovarian cancer cell line HO-8910 with silencing of the ZNF217 gene.

Authors:  Guiqin Sun; Jingxia Qin; Yuwen Qiu; Yunfei Gao; Yanhong Yu; Qinkai Deng; Mei Zhong
Journal:  Mol Med Rep       Date:  2009 Sep-Oct       Impact factor: 2.952

2.  Decreased expression of hsa_circ_001988 in colorectal cancer and its clinical significances.

Authors:  Xuning Wang; Yue Zhang; Liang Huang; Jiajin Zhang; Fei Pan; Bing Li; Yongfeng Yan; Baoqing Jia; Hongyi Liu; Shiyou Li; Wei Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 3.  The natural history of human papillomavirus infection.

Authors:  Silvia de Sanjosé; Maria Brotons; Miguel Angel Pavón
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2017-09-06       Impact factor: 5.237

4.  Clinical Significance of Integrin Subunit Beta 4 in Head and Neck Squamous Cell Carcinoma.

Authors:  Guo-Sheng Li; Wei Hou; Gang Chen; Yu-Xuan Yao; Xiao-Yi Chen; Xiao-Guohui Zhang; Yao Liang; Ming-Xuan Li; Zhi-Guang Huang; Yi-Wu Dang; Qing-Hua Liang; Hua-Yu Wu; Rong-Qiao Li; Hong-Yu Wei
Journal:  Cancer Biother Radiopharm       Date:  2020-11-11       Impact factor: 3.099

5.  Circular RNA hsa_circ_0061825 (circ-TFF1) contributes to breast cancer progression through targeting miR-326/TFF1 signalling.

Authors:  Gaofeng Pan; Anwei Mao; Jiazhe Liu; Jingfeng Lu; Junbin Ding; Weiyan Liu
Journal:  Cell Prolif       Date:  2020-01-21       Impact factor: 6.831

  5 in total
  1 in total

Review 1.  MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.

Authors:  Janusz Matuszyk
Journal:  Mol Med       Date:  2022-08-03       Impact factor: 6.376

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.